Proteomics International Laboratories' (ASX:PIQ) subsidiary, OxiDx, received an intellectual property patent in China for its platform technology designed to precisely measure levels of oxidative stress, according to a Thursday filing with the Australian bourse.
The patent is valid until 2039. Aside from China, OxiDx's technology has intellectual protection in the US, Japan, Europe, and Australia. The company's application for a second-generation patent is pending in the US, Singapore, and India, the filing stated.
The medical technology company's shares were up over 1% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.